All articles by Anthony King – Page 14
-
BusinessBrexit uncertainty ripples across regulation
What might leaving the EU mean for medicines regulation, the Unified Patent Court, and the UK’s participation in Reach?
-
ResearchModel hints at prebiotic chemistry on Titan
Saturn’s largest moon may be rich in hydrogen cyanide based polymers
-
BusinessSanofi and Boehringer agree €11bn asset swap
Deal swaps Sanofi’s animal health arm for Boehringer’s consumer healthcare business as both firms aim to boost scale
-
NewsWorld faces tough challenge turning words into action on antibiotic resistance
Countries are waking up to the challenge of ‘superbugs’ but agreeing a way forward will be tricky
-
NewsAudience reactions alter cinema atmosphere
The emotional content of a film affects the skin and breath volatiles given off by cinema goers
-
-
BusinessAbbot boosts heart devices with St Jude buyout
Medical devices consolidation continues with $25bn deal, but Abbott expresses concerns over proposed Alere merger
-
ResearchEarthly xenon’s asteroid origins reveal planet’s genesis
Discovery that atmospheric xenon is unrelated to that in the mantle hints at two separate extra-terrestrial ‘deliveries’ of the element
-
-
BusinessUS treasury rules scupper Pfizer–Allergan merger
Government aims to crack down on corporate tax avoidance through ‘inversion’ deals
-
News
Irish institute in hot water with university ranking agency
Quacquarelli Symonds unhappy with emails sent to academics asking them to take part in survey
-
NewsAntibiotic alternatives need to be recruited in fight against resistance
Vaccines, probiotics and other substitutes could help battle antimicrobial resistance as antibiotic effectiveness fades
-
BusinessOil slump reverberates in chemicals
Collapse in crude prices has complex and mixed effects on markets for derivative chemicals
-
FeatureA volatile question
VOCs are more than just a man-made problem. Anthony King looks through the wood to the trees
-
NewsPressure on controversial nanoparticle paper builds
Expression of concern and reprimand for chemists may seal fate of work on palladium particles
-
BusinessShire bets big on rare diseases
$32bn Baxalta buyout will deepen Shire’s commitment to developing specialist drugs for small patient populations
-
BusinessDow and DuPont mega-merger heralds break-up of giants
New firm will split itself in speciality, agrichemical and materials businesses with R&D taking a hit from cost savings
-
NewsAll boats to be lifted by Irish science strategy
Ambitious plan to double research spending relies on tapping the private sector to provide two-thirds of the money
-
NewsReview calls for tighter controls on antibiotic use in farming
Legally binding targets are needed to tackle resistance worldwide, latest report says
-
